LG AI Research, part of the South Korean LG Group, has introduced an updated version of its artificial intelligence model, EXAONE Path 2.0, designed for pathology research.

This was reported by Yonhap.

The laboratory indicated that compared to the previous version 1.0, EXAONE Path 2.0 offers enhanced accuracy in analyzing and predicting genetic mutations, gene expression patterns, and minor structural changes in human cells and tissues, utilizing images of pathological samples.

It was noted that the model was trained on over 10,000 datasets, covering visualization and multi-omics, allowing it to predict gene activity solely based on image analysis, without the need for expensive genomic testing.

“With EXAONE Path 2.0, genetic testing can be completed in under a minute, compared to more than two weeks previously required. This will save critical time in treating cancer patients,” said LG AI Research's lead researcher, Park Yong-min.

He added that doctors and pharmaceutical companies can utilize EXAONE Path 2.0 for rapid analysis of pathological images in cancer patients, detecting gene mutations, and selecting appropriate targeted therapies.

As reported by Ukrinform, the Chinese company DeepSeek has unveiled an updated AI model, DeepSeek R1, thereby intensifying its competition with OpenAI, the developer of the popular chatbot ChatGPT.